The 3 + 3 design is the most common choice among clinicians for phase I dose-escalation oncology trials. In recent reviews, more than 95% of phase I trials have been based on the 3 + 3 design. Given ...
Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress In contemporary phase I trials, which often include drugs developed with a deep understanding of biology and with the use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results